Skip to search formSkip to main contentSkip to account menu

0.2 ML ocriplasmin 2.5 MG/ML Injection

Known as: ocriplasmin 0.5 MG in 0.2 ML Injection, OCRIPLASMIN 0.5MG/0.2ML OPH INJ, OCRIPLASMIN 0.5MG/0.2ML INJ,OPH [VA Product] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
of primary RRD is seen in many centres around the world (FalknerRadler et al. 2011; Wong et al. 2014). The role of PPV is likely… 
Review
2018
Review
2018
Purpose: To investigate predictors of success, visual outcomes, and complications of intravitreal ocriplasmin for the treatment… 
2017
2017
Hintergrund Bei der vitreomakularen Traktion (VMT) besteht eine abnormal starke Adharenz zwischen Netzhaut und Glaskorperkortex… 
Review
2016
Review
2016
ZusammenfassungHintergrundDie Behandlung einer vitreomakulären Traktion (VMT) mit Ocriplasmin (Jetrea®) war in großen Phase-3… 
2016
2016
Purpose: To assess the stiffness of the human internal limiting membrane (ILM) and evaluate potential changes of mechanical… 
Review
2015
Review
2015
Purpose: To report initial experience with intravitreal ocriplasmin (IVO) and to describe outer retina reflectivity changes… 
2015
2015
PurposeTo evaluate prospectively the anatomical and functional results after ocriplasmin injection in patients with vitreomacular… 
2014
2014
Vitreomacular traction and vitreomacular traction with macular hole are conditions associated with visual disturbance and… 
Highly Cited
2014
Highly Cited
2014
IMPORTANCE Ocriplasmin cleaves fibronectin and laminin, components of the vitreous gel, and is used as a pharmacologic treatment… 
Highly Cited
2014
Highly Cited
2014
IMPORTANCE Clinical trials indicate that visual impairment is significantly greater in patients receiving ocriplasmin than…